利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

34 条记录 (耗时 0.025 秒)

    Membrane bound stem cell factor therapy for ischemic heart
    1.
    发明授权
    Membrane bound stem cell factor therapy for ischemic heart 有权
    膜结合干细胞因子治疗缺血性心脏

    公开(公告)号：US08404653B2

    公开(公告)日：2013-03-26

    申请号：US12084673

    申请日：2006-11-13

    申请人： Krisztina M. Zsebo

    发明人： Krisztina M. Zsebo

    IPC分类号： A61K48/00 ,  A01N63/00

    CPC分类号： A61K48/005

    摘要： The present invention relates to the use of stem cell factor (SCF) for the treatment of ischemic injured tissue such as in cardiovascular disease. The method involves administration of a nucleic acid encoding SCF, wherein the nucleic acid is delivered to the site of the injury and is incorporated into cells which then express the SCF.

    摘要翻译： 本发明涉及干细胞因子（SCF）用于治疗缺血性损伤组织如心血管疾病的用途。 该方法涉及施用编码SCF的核酸，其中所述核酸被递送到损伤部位，并且被并入然后表达SCF的细胞中。

    Production of antibodies using cre-mediated site-specific recombination
    2.
    发明授权
    Production of antibodies using cre-mediated site-specific recombination 有权

    公开(公告)号：US07145056B2

    公开(公告)日：2006-12-05

    申请号：US10210425

    申请日：2002-07-31

    申请人： Aya Jakobovits ,  Krisztina M. Zsebo

    发明人： Aya Jakobovits ,  Krisztina M. Zsebo

    IPC分类号： A61J67/00 ,  A61J48/00 ,  C12N5/00 ,  C12N15/00 ,  C12N15/63

    CPC分类号： C12N15/90 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/03 ,  C07K16/00 ,  C12N15/8509 ,  C12N2800/30

    摘要： A method to produce a cell expressing an antibody from a genomic sequence of the cell comprising a modified immunoglobulin locus using Cre-mediated site-specific recombination is disclosed. The method involves first transfecting an antibody-producing cell with a homology-targeting vector comprising a lox site and a targeting sequence homologous to a first DNA sequence adjacent to the region of the immunoglobulin loci of the genomic sequence which is to be converted to a modified region, so the first lox site is inserted into the genomic sequence via site-specific homologous recombination. Then the cell is transfected with a lox-targeting vector comprising a second lox site suitable for Cre-mediated recombination with the integrated lox site and a modifying sequence to convert the region of the immunoglobulin loci to the modified region. This conversion is performed by interacting the lox sites with Cre in vivo, so that the modifying sequence inserts into the genomic sequence via Cre-mediated site-specific recombination of the lox sites. Also disclosed are a form of the method used to produce a cell expressing a modified antibody molecule using Cre-mediated site-specific recombination, and antibody-producing cells obtainable by the disclosed methods. Class-switching modifications of human antibodies produced in murine hybridoma cells are exemplified.

    Production of antibodies using Cre-mediated site-specific recombination
    4.
    发明授权
    Production of antibodies using Cre-mediated site-specific recombination 失效

    公开(公告)号：US06130364A

    公开(公告)日：2000-10-10

    申请号：US412826

    申请日：1995-03-29

    申请人： Aya Jakobovits ,  Krisztina M. Zsebo

    发明人： Aya Jakobovits ,  Krisztina M. Zsebo

    IPC分类号： C12N15/09 ,  C07K16/00 ,  C12N5/10 ,  C12N15/85 ,  C12N15/90 ,  C12P21/02 ,  A01K67/00 ,  C12N15/00

    CPC分类号： C12N15/90 ,  C07K16/00 ,  C12N15/8509 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/03 ,  C12N2800/30

    摘要： A method to produce a cell expressing an antibody from a genomic sequence of the cell comprising a modified immunoglobulin locus using Cre-mediated site-specific recombination is disclosed. The method involves first transfecting an antibody-producing cell with a homology-targeting vector comprising a lox site and a targeting sequence homologous to a first DNA sequence adjacent to the region of the immunoglobulin loci of the genomic sequence which is to be converted to a modified region, so the first lox site is inserted into the genomic sequence via site-specific homologous recombination. Then the cell is transfected with a lox-targeting vector comprising a second lox site suitable for Cre-mediated recombination with the integrated lox site and a modifying sequence to convert the region of the immunoglobulin loci to the modified region. This conversion is performed by interacting the lox sites with Cre in vivo, so that the modifying sequence inserts into the genomic sequence via Cre-mediated site-specific recombination of the lox sites. Also disclosed are a form of the method used to produce a cell expressing a modified antibody molecule using Cre-mediated site-specific recombination, and antibody-producing cells obtainable by the disclosed methods. Class-switching modifications of human antibodies produced in murine hybridoma cells are exemplified.

    Stem Cell Factor Therapy for Tissue Injury
    6.
    发明申请
    Stem Cell Factor Therapy for Tissue Injury 有权
    干细胞因子治疗组织损伤

    公开(公告)号：US20090304636A1

    公开(公告)日：2009-12-10

    申请号：US12084673

    申请日：2006-11-13

    申请人： Krisztina M. Zsebo

    发明人： Krisztina M. Zsebo

    IPC分类号： A61K31/7088 ,  A61K35/76 ,  A61K35/12

    CPC分类号： A61K48/005

    摘要： The present invention relates to the use of stem cell factor (SCF) for the treatment of ischemic injured tissue such as in cardiovascular disease. The method involves administration of a nucleic acid encoding SCF, wherein the nucleic acid is delivered to the site of the injury and is incorporated into cells which then express the SCF.

    摘要翻译： 本发明涉及干细胞因子（SCF）用于治疗缺血性损伤组织如心血管疾病的用途。 该方法涉及施用编码SCF的核酸，其中所述核酸被递送到损伤部位，并且被并入然后表达SCF的细胞中。